• Scottish Medicines Consortium Approves Kyprolis-Dexamethasone Combo for Previously Treated Multiple Myeloma Patients
  • Cellectar’s CLR 131 Shows Early Promising Survival Outcomes in Phase 1 Trial of Relapsed or Refractory Myeloma
  • PharmaMar Launches Aplidin Quadruple Combo Trial in Myeloma
  • VAX-DC/MM Cell Therapy Shows Promise in Relapsed or Refractory Myeloma, Lymphoma Patients
  • Imbruvica Becomes 1st FDA-Approved Therapy for Graft-Versus-Host-Disease in Adults
  • STRO-001 Eliminates or Slows Growth of Myeloma and Lymphoma in Mice, Studies Show
  • Revlimid Therapy May Delay Myeloma Progression and Increase Survival
  • Stem Cell Transplants Work for Many Myeloma Patients Who Fail to Respond to First-line Therapies, Study Finds
  • Systemic Gaps in Cancer Care Are Detrimental to Patient Outcomes, Survey Finds
  • Kyprolis-Dexamethasone Combo Allows Relapsed Myeloma Patients to Live Longer, Amgen Says
  • Kyprolis Regimen Reduces Risk of Death in Relapsed Multiple Myeloma Patients, Studies Show
  • KD025 Shows Promise for Chronic Graft-Versus-Host Disease, a Common Complication of Stem Cell Transplants